Rogaratinib (BAY 1163877)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Rogaratinib (BAY 1163877), covering 2026-04-13 to 2026-04-13. Get the full timeline:
Most recent: Clinical Trial Update: Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST) [Phase 2]